
CI
USDThe Cigna Group Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$257.700
Máximo
$264.800
Mínimo
$256.000
Volumen
3.20M
Fundamentos de la Empresa
Capitalización de Mercado
70.7B
Industria
Healthcare Plans
País
United States
Estadísticas de Negociación
Volumen Promedio
1.74M
Bolsa
NYQ
Moneda
USD
Rango de 52 Semanas
Informe de Análisis de IA
Última actualización: 3 nov 2025Cigna (CI) Stock Analysis: Finding Opportunity in Recent Turmoil
What Happened to Cigna's Stock?
Cigna took a serious hit recently. On October 30th, shares plunged 18% to $247.10 on massive volume - nearly 5.5 times their average trading activity. The selling continued the next day, dropping the stock to $244.41. This puts CI dangerously close to its 52-week low of $240.67.
What's puzzling is this crash happened despite generally positive news. The company beat Q3 earnings estimates, Goldman Sachs just initiated coverage with a strong Buy rating and $370 price target (that's 50% above current levels), and they announced meaningful initiatives to reduce medication costs for Americans.
Reading Between the Price Lines
Let's unpack what's really happening with Cigna's chart:
- The Setup: Through most of August and September, CI built a solid upward trend, climbing from $260 to over $310
- The Breakdown: After peaking near $315, the stock drifted lower through October
- The Crash: That October 30th drop was no ordinary correction - it was a full-blown panic sell-off
Here's what stands out: the volume spike on October 30th wasn't normal distribution. When volume jumps that high during a sharp decline, it usually means big institutional players are exiting positions all at once. The good news? The selling pressure appears exhausted - the follow-through day on October 31st showed much weaker volume.
Why This Might Be Your Entry Window
Three compelling reasons suggest the worst may be over:
-
Technical Signals Flashing Green: The stock now sits right at its support level ($244.33). When prices bounce off support with conviction, it often marks a turning point. Right now, the distance between current price and support is practically nonexistent - meaning we're at the make-or-break point.
-
Goldman's Confidence: Their $370 price target isn't some random number. At current levels, that represents serious upside potential. What's interesting is they're not alone - 24 analysts maintain strong buy ratings.
-
The News/Price Disconnect: Positive earnings, strategic initiatives, and dividend stability shouldn't result in an 18% single-day drop. This mismatch creates what traders call "mispricing" - a temporary gap between actual value and market price
Noticias Relacionadas
Analysts Lower Cigna Targets As PBM Segment Guidance Surprises Market
Cigna expects 2026–2027 margin pressure from its new rebate-free PBM model as major clients renew at lower margins, prompting analyst target cuts.
TD Cowen Maintains Buy on Cigna Group, Lowers Price Target to $333
TD Cowen analyst Charles Rhyee maintains Cigna Group with a Buy and lowers the price target from $387 to $333.
Goldman Sachs Maintains Buy on Cigna Group, Lowers Price Target to $330
Goldman Sachs analyst Scott Fidel maintains Cigna Group with a Buy and lowers the price target from $370 to $330.
JP Morgan Maintains Overweight on Cigna Group, Lowers Price Target to $375
JP Morgan analyst Lisa Gill maintains Cigna Group with a Overweight and lowers the price target from $428 to $375.
Barclays Maintains Overweight on Cigna Group, Lowers Price Target to $300
Barclays analyst Andrew Mok maintains Cigna Group with a Overweight and lowers the price target from $383 to $300.
Health insurer Cigna beats quarterly profit estimates on health services strength
Cigna Group beat Wall Street estimates for third-quarter profit on Thursday, driven by strength in the company's health services unit Evernorth that houses its pharmacy benefit management business.
Evernorth Announces New Era of Pharmacy Benefit Services to Lower Americans' Medication Costs
Evernorth, the health services division of The Cigna Group (NYSE:CI) today announced a new rebate-free pharmacy benefit model designed to help...
Predicción de IABeta
Recomendación de IA
Actualizado el: 5 nov 2025, 05:51
68.6% Confianza
Riesgo y Negociación
Punto de Entrada
$244.87
Toma de Ganancias
$249.29
Stop Loss
$219.96
Factores Clave
Acciones Relacionadas
NMTC
NeuroOne Medical Technologies Corporation
ORMP
Oramed Pharmaceuticals Inc.
TAK
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)
CLOV
Clover Health Investments Corp.
MSFT
Microsoft Corporation
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.